Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) has become the reference imaging modality across the natural history of prostate cancer (PC) [1], while PSMA-targeted radioligand therapy (RLT) is now an established treatment option in the post-taxane castration-resistant setting, with encouraging data in earlier disease phases also emerging. Despite this success, PSMA is not without limitations. Nonspecific bone uptake can complicate image interpretation and [2] requires careful clinical interpretation.
Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) has become the reference imaging modality across the natural history of prostate cancer (PC) [1], while PSMA-targeted radioligand therapy (RLT) is now an established treatment option in the post-taxane castration-resistant setting, with encouraging data in earlier disease phases also emerging. Despite this success, PSMA is not without limitations. Nonspecific bone uptake can complicate image interpretation and [2] requires careful clinical interpretation.